Quarterly ResultMay 5, 2026, 08:32 AM
Disc Medicine Completes Bitopertin Phase 3 Enrollment; Q1 Net Loss $63.5M
AI Summary
Disc Medicine reported Q1 2026 financial results and provided significant clinical pipeline updates. The company completed enrollment for its Phase 3 APOLLO study of bitopertin in EPP, with topline data anticipated in Q4 2026. Updated Phase 2 data for DISC-0974 in myelofibrosis anemia will be presented at ASCO. Studies for DISC-3405 in polycythemia vera and sickle cell disease are progressing, with data expected in Q4 2026. The company ended Q1 with $730.2 million in cash, providing a runway into 2029, despite a net loss of $63.5 million.
Key Highlights
- Completed enrollment of Phase 3 APOLLO study for bitopertin in EPP; topline data expected Q4 2026.
- Updated Phase 2 data for DISC-0974 in MF anemia to be presented at ASCO in June (N=61 patients).
- Topline data from DISC-0974 RALLY-MF study expected Q4 2026.
- Initial data from DISC-3405 Phase 2 (PV) and Phase 1b (SCD) studies expected Q4 2026.
- Cash, cash equivalents, and marketable securities were $730.2 million as of March 31, 2026.
- Net loss for Q1 2026 was $63.5 million, compared to $34.1 million in Q1 2025.
- R&D expenses increased to $45.9 million in Q1 2026 from $27.8 million in Q1 2025.
- SG&A expenses increased to $23.6 million in Q1 2026 from $12.2 million in Q1 2025.